Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747351 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
- 20
- Study locations
NCT06747351 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) that is actively recruiting participants, run by Takeda. The registered enrollment target is 59 participants, above the 33-participant average among 3 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT06747351, a Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP. The participants who are already receiving intravenous immunoglobulin G (IGIV), conventional subcutaneous intravenous immunoglobulin G (cIGSC), or HYQVIA will be treated with the same dose equivalent as their prior IG treatment with HYQVIA for 20 weeks followed by TAK-881 for 24 weeks. Participants will need to visit the clinic every 3 or 4 weeks until they enter the extension phase. In the extension phase, home infusions are allowed, and visits will occur between every 12 weeks and 24 weeks.
Conditions Studied
Interventions
- BIOLOGICAL TAK-881
- BIOLOGICAL HYQVIA
- DEVICE SC Investigational Needle Sets
Study Locations (20)
North Carolina
- University of North Carolina (UNC) - Chapel Hill
- Duke University Hospital - Durham
- Raleigh Neurology Associates - Raleigh
- Atrium Health Wake Forest Baptist - Winston-Salem
Florida
- Neurology Associates - Maitland
- Knight Neurology - Rockledge
Other
- Instituto Argentino de Investigacion Neurologica (IADIN) - Buenos Aires
- Fakultni nemocnice Hradec Kralove - Hradec Králové
Arizona
- HonorHealth Neurology - Scottsdale
California
- Stanford Neuroscience Health Center - Palo Alto
Connecticut
- Yale University School of Medicine - New Haven
Missouri
- The Washington University - St Louis
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2028-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06747351
The ClinicalTrials.gov registry entry for NCT06747351 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 33-participant average among 3 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials with a reported enrollment target (79% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) appearing as the primary indexed condition, and to 3 interventions - of which TAK-881 is the first listed.
NCT06747351 reports 20 study locations spanning 15 distinct geographic areas - top geographies include North Carolina, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT06747351 about?
NCT06747351 is a clinical study titled "A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)". The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP. The participants who are already receiving intravenous immunoglobulin G (IGIV), conventional subcutaneous intravenous immunog...
What is the current status of trial NCT06747351?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2025-05-06. Estimated completion is 2028-06-25.
What conditions does trial NCT06747351 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).
What interventions are being tested in trial NCT06747351?
The interventions under investigation include: TAK-881 (BIOLOGICAL), HYQVIA (BIOLOGICAL), SC Investigational Needle Sets (DEVICE).
Who is sponsoring clinical trial NCT06747351?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747351 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
RECRUITING
-
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.